Nitric Oxide-Releasing Macromolecule Exhibits Broad-Spectrum Antifungal Activity and Utility as a Topical Treatment for Superficial Fungal Infections

Antimicrobial Agents and Chemotherapy
Nathan StaskoRyan Doxey

Abstract

Cutaneous and superficial fungal infections affecting the skin, nails, and hair of humans are caused primarily by dermatophytes of the genera Trichophyton and Epidermophyton or by yeasts of the genera Candida and Malassezia. Onychomycosis is a common fungal infection of the nail that frequently coexists with tinea pedis, the most prevalent mycotic skin infection. Efficacy rates for current topical onychomycosis therapies are hampered by low drug penetration across the nail plate, which is theoretically obviated with nitric oxide (NO)-based topical therapies. The Nitricil technology platform is comprised of polysiloxane-based macromolecules that stably release therapeutic levels of NO. In the reported studies, NVN1000, the lead candidate of the platform, was assessed for its spectrum of in vitro activity against a broad range of filamentous fungi and yeast species commonly associated with cutaneous fungal infections. Time-kill assays demonstrated that NVN1000 exhibited fungicidal activity as early as 4 h. Additionally, the penetration of several unique NVN1000 NO-releasing drug product formulations (gel, cream, and lacquer) was evaluated following a single topical application in an in vitro infected human nail assay, with all fo...Continue Reading

References

Mar 11, 1998·Lancet·A K Gupta, R K Scher
Jun 15, 1999·Journal of the American Academy of Dermatology·R K Scher
Aug 2, 2000·Proceedings of the National Academy of Sciences of the United States of America·C Nathan, M U Shiloh
Sep 27, 2003·The British Journal of Dermatology·R K Scher, R Baran
Apr 21, 2004·Journal of the American Academy of Dermatology·K Wade FosterBoni E Elewski
Sep 21, 2004·Nature Reviews. Microbiology·Ferric C Fang
Sep 29, 2005·Nitric Oxide : Biology and Chemistry·A GhaffariA Ghahary
Jan 24, 2007·Physiological Reviews·Pál PacherLucas Liaudet
Mar 23, 2007·Journal of the American Chemical Society·Jae Ho ShinMark H Schoenfisch
Jul 11, 2007·Journal of Pharmaceutical Sciences·Xiaoying HuiHoward I Maibach
Dec 15, 2007·Nature Reviews. Microbiology·Mihai G NeteaNeil A R Gow
Sep 16, 2008·Nitric Oxide : Biology and Chemistry·Chris MillerYossef Av-Gay
Mar 9, 2010·Molecular Pharmaceutics·Ellen V StevensMark H Schoenfisch
Jul 20, 2010·The Journal of Pharmacy and Pharmacology·M J TraynorM B Brown
Feb 22, 2012·Nitric Oxide : Biology and Chemistry·Benjamin J PrivettMark H Schoenfisch
Apr 5, 2012·Pediatrics in Review·Brendan P Kelly
Oct 23, 2012·Journal of Applied Microbiology·G Regev-ShoshaniC C Miller
Oct 3, 2015·Journal of the American Podiatric Medical Association·Bryan Markinson, Bryan Caldwell
May 11, 2016·Cutaneous and Ocular Toxicology·Alain Stricker-KrongradGuy Bouchard

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.